Trial | NCT01008345  Report issue

Title

Effect of Ezetimibe on Oxidized Low-density Lipoprotein (LDL) Cholesterol
Effect of Ezetimibe on Oxidized LDL Cholesterol

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    ezetimibe ...

  • Study Participants

    100
Randomized study. Patients with coronary artery disease equivalent will be randomized to receive atorvastatin 40 mg/day + placebo vs. atorvastatin 40 mg/day + ezetimibe 40 mg/day. Oxidized LDL cholesterol will be measured at baseline and after 8 weeks of treatment. Hypothesis is that ezetimibe will lower oxidized LDL
Study Started
Sep 30
2008
Primary Completion
Jun 30
2009
Study Completion
Jun 30
2009
Last Update
Nov 06
2009
Estimate

Drug ezetimibe

Patients will receive 10 mg/day of ezetimibe for 8 weeks

ezetimibe Experimental

will receive the active treatment with ezetimibe and statin

placebo Placebo Comparator

Criteria 

Inclusion Criteria:

CAD or CAD equivalent

Exclusion Criteria:

Prior CABG or PCI within 3 months Prior use of ezetimibe within 3 months Receiving atorvastatin 40 mg/day or 80 mg/day or any dose of rosuvastatin CHF NYHA stage >2 Creatinin clearance < 30 ml/min
No Results Posted